Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Tavlesse on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Spain
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tavlesse (fostamatinib) is a spleen tyrosine kinase (SYK) inhibitor approved in the European Union and United Kingdom for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. Tavlesse is marketed in Europe by Grifols under license from Rigel Pharmaceuticals, which markets the same active ingredient in the United States under the brand name Tavalisse.
Tavlesse inhibits spleen tyrosine kinase (SYK), a protein involved in the antibody-mediated destruction of platelets that occurs in immune thrombocytopenia. By blocking SYK signaling, Tavlesse helps reduce platelet destruction and increase platelet counts.
Tavlesse is intended for adults with chronic ITP who have not achieved an adequate platelet response with a previous ITP treatment, such as corticosteroids, immunoglobulins, or other standard therapies.
The recommended starting dose of Tavlesse is 100 mg orally twice daily, which may be increased to 150 mg twice daily after four weeks if platelet counts remain below 50 x 10⁹/L.
Tavlesse does not use the FDA-style formal boxed warning format, as it is marketed under the EU/UK regulatory framework. However, patients and prescribers should be aware of the following important safety information.
New or worsening hypertension, including hypertensive crisis, has been reported. Blood pressure should be monitored before and regularly during treatment.
Liver function tests should be monitored monthly during the first several months of treatment, as liver enzyme elevations have been observed.
Severe diarrhea and neutropenia have been reported and may require dose modification or interruption.
Tavlesse may cause fetal harm and is contraindicated during pregnancy. Effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tavlesse is marketed by Grifols for the EU and UK markets, under license from Rigel Pharmaceuticals. It is sourced through authorized European distribution channels for patients seeking named-patient import into India. The same active ingredient, fostamatinib, is marketed in the United States under the brand name Tavalisse.
Patients typically need a valid prescription from a treating hematologist confirming chronic ITP diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an EU/UK-approved therapy for chronic ITP, Tavlesse is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Tavlesse directly from authorized European pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tavlesse should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Tavlesse through NPP's regulated import pathway, with hematology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology care coordination and documentation for Tavlesse access.
Delhi's major hospitals assist patients with prescription support and documentation for Tavlesse.
Bangalore's specialist network offers access coordination for eligible ITP patients seeking Tavlesse.
Chennai-based hematology specialists coordinate Tavlesse access alongside comprehensive ITP care.
Hyderabad's care institutions support patients pursuing Tavlesse therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tavlesse.
Pune-based specialists assist with prescription support and Tavlesse treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tavlesse.
Kochi's specialist units assist patients with the documentation needed for Tavlesse access.
Chandigarh's care centers support Tavlesse treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tavlesse access process.
Lucknow-based centers assist patients pursuing Tavlesse therapy.
Bhubaneswar's institutions support access to Tavlesse for eligible patients.
Guwahati's specialists help coordinate Tavlesse access for patients across the Northeast.
Patients in other cities across India can also access Tavlesse through NPP's nationwide coordination network.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: UK emc (SmPC), FDA (Tavalisse US label cross-reference)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
